Biomunex Pharmaceuticals signs a licensing agreement with Sanofi
February 14, 2019
Dechert LLP advised Biomunex Pharmaceuticals, a biopharmaceutical company focused on providing immuno-therapeutics through the discovery and development of bi- and multi-specific antibodies, in its announced licensing agreement with Sanofi.
Under the terms of the agreement, Sanofi will have access to Biomunex’ proprietary technology to generate and optimize bi- and multi-specific antibody therapeutics.
This agreement, the first of its kind for Biomunex, is in line with the company’s business model, which is to establish licensing or collaboration agreements and to become a clinical-stage company in the short term.
The Paris-based team advising Biomunex on the legal aspects was led by National Partner Marie Fillon, head of the intellectual property group. The team also included Partner Anne-Charlotte Rivière (Corporate & Securities), Partner Sabina Comis and associate Pierre-Emmanuel Floc’h (Tax).
About Dechert
Dechert is a leading global law firm with 27 offices around the world. We advise on matters and transactions of the greatest complexity, bringing energy, creativity and efficient management of legal issues to deliver commercial and practical advice for clients.
Related Professionals
